Clinical and hematologic outcome measures by disease severity
| Variable . | Total . | Severe . | Uncomplicated . | P . |
|---|---|---|---|---|
| Primary antimalarial drug: quinine/artesunate or DHA | 7, 13 | 4, 10 | 3, 3 | .6 |
| Secondary oral antimalarial drug: doxycycline/mefloquine | 11, 9 | 7, 7 | 4, 2 | .6 |
| FCTB, hr† | 53 (5-114) | 65 (16-114) | 43 (5-63) | .4 |
| Parasite clearance time, hr† | 66 (30-108) | 66 (30-108) | 60 (30-84) | .3 |
| PRR0-24 hr† | 11 (1-1335) | 11 (1-550) | 11 (9-1335) | .3 |
| Peak reticulocyte count/μL*,2-153 | 58 668 (32 319-85 018) | 241 690 (165 976-317 405) | 181 450 (130 503-232 397) | .3 |
| Peak RESA-RBC count/μL‡,2-153 | 66 237 (48 809-89 888) | 64 432 (41 745-99 472) | 70 632 (47 687-104 592) | .8 |
| Time to peak RESA-RBC count, hr† | 46 (2-548) | 41 (2-548) | 47 (12-264) | .7 |
| Mean RESA-RBC life, hr‡ | 183 (136-246) | 180 (122-266) | 193 (118-315) | .9 |
| Mean red cell life, hr* | 1027 (840-1213) | 957 (712-1203) | 1177 (839-1516) | .3 |
| RESA-RBC MRT, hr* | 282 (233-332) | 283 (217-348) | 282 (185-378) | 1.0 |
| No. with RESA antibodies detected | 5 | 5 | 0 | .3 |
| Fractional RESA-RBC increment, RESA-RBC peak† | 4.0 (0.3-17.0) | 2.2 (0.3-17.0) | 4.1 (2.0-9.9) | .3 |
| Fractional RESA-RBC increment, 24 hr† | 1.4 (−0.2-9.2) | 1.1 (−0.2-9.2) | 2.0 (0.4-7.7) | .3 |
| RESA-RBC increment:parasite decrement ratio†,2-155 | 0.2:1.0 (0.1:1.0-3.8:1.0) | 0.2:1.0 (0.1:1.0-1.3:1.0) | 0.5:1.0 (0.1:1.0-3.8:1.0) | .3 |
| Variable . | Total . | Severe . | Uncomplicated . | P . |
|---|---|---|---|---|
| Primary antimalarial drug: quinine/artesunate or DHA | 7, 13 | 4, 10 | 3, 3 | .6 |
| Secondary oral antimalarial drug: doxycycline/mefloquine | 11, 9 | 7, 7 | 4, 2 | .6 |
| FCTB, hr† | 53 (5-114) | 65 (16-114) | 43 (5-63) | .4 |
| Parasite clearance time, hr† | 66 (30-108) | 66 (30-108) | 60 (30-84) | .3 |
| PRR0-24 hr† | 11 (1-1335) | 11 (1-550) | 11 (9-1335) | .3 |
| Peak reticulocyte count/μL*,2-153 | 58 668 (32 319-85 018) | 241 690 (165 976-317 405) | 181 450 (130 503-232 397) | .3 |
| Peak RESA-RBC count/μL‡,2-153 | 66 237 (48 809-89 888) | 64 432 (41 745-99 472) | 70 632 (47 687-104 592) | .8 |
| Time to peak RESA-RBC count, hr† | 46 (2-548) | 41 (2-548) | 47 (12-264) | .7 |
| Mean RESA-RBC life, hr‡ | 183 (136-246) | 180 (122-266) | 193 (118-315) | .9 |
| Mean red cell life, hr* | 1027 (840-1213) | 957 (712-1203) | 1177 (839-1516) | .3 |
| RESA-RBC MRT, hr* | 282 (233-332) | 283 (217-348) | 282 (185-378) | 1.0 |
| No. with RESA antibodies detected | 5 | 5 | 0 | .3 |
| Fractional RESA-RBC increment, RESA-RBC peak† | 4.0 (0.3-17.0) | 2.2 (0.3-17.0) | 4.1 (2.0-9.9) | .3 |
| Fractional RESA-RBC increment, 24 hr† | 1.4 (−0.2-9.2) | 1.1 (−0.2-9.2) | 2.0 (0.4-7.7) | .3 |
| RESA-RBC increment:parasite decrement ratio†,2-155 | 0.2:1.0 (0.1:1.0-3.8:1.0) | 0.2:1.0 (0.1:1.0-1.3:1.0) | 0.5:1.0 (0.1:1.0-3.8:1.0) | .3 |
FCTB indicates fever clearance time, the time at which the fever first falls below 37.5°C and remains below for 24 hours; PRR0-24 hr, parasite reduction ratio 24 hr:0 hr.
Mean (95% CI).
Median (range).
Geometric mean (95% CI).
See Table 1.
Ratio of RESA-RBC count increase to RESA-RBC peak/parasitemia decrease to time of RESA-RBC peak.